Previous close | 65.00 |
Open | 63.50 |
Bid | 56.50 x 0 |
Ask | 57.50 x 0 |
Day's range | 63.00 - 63.50 |
52-week range | 63.00 - 125.00 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 24 July 2024 - 29 July 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.
Conmed Corp reports significant improvements in sales, net income, and operational efficiency, alongside strategic discussions on competitive positioning and market expansions.
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.